WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-approved CorPath System at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2013 annual meeting, Oct. 27 – Nov. 1 in San Francisco, CA. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Experts from renowned hospitals and healthcare organizations across the country will deliver onsite presentations and answer questions about their clinical experience with robotic-assisted angioplasty and the significant advantages in stent precision and clinical outcomes utilizing the CorPath System.
Physician presentations will be highlighted during, “Optimizing PCI with Robotic Angioplasty,” a breakfast symposium co-sponsored by Philips Healthcare on Wednesday, Oct. 30, at 7:00 a.m. PDT at Moscone North, Lower Level, Room 122 at the Moscone Center.
Moderated by J. Jeffrey Marshall, M.D., FACC, FSCAI, Northeast Georgia Heart Center, and Giora Weisz, M.D., NewYork-Presbyterian Hospital/Columbia University Medical Center, “Optimizing PCI with Robotic Angioplasty” will feature presentations on the advantages offered by robotic-assisted percutaneous coronary intervention (PCI) procedures, followed by an audience discussion and Q&A on future directions of vascular robotics.
“Robotic assistance in angioplasties has shone a light on the considerable room for improvement in invasive vascular procedures, particularly in terms of stent size selection and precision in optimal placement of stents in PCI procedures,” said Dr. Marshall. “The linkage between the use of robotics during PCIs and improvement in clinical outcomes continues to increase, and the trend stands to gain further support as the interventional cardiology field embraces a future enabling the delivery of better care.”
In addition to the breakfast symposium, Dr. Weisz will also present, “Robotic Percutaneous Cardiovascular Intervention: Current Status and Future Directions” during “25 Years of Interventional Innovation: Novel Therapies and the ’Emerging’ Device Concepts for 2013,” a scientific symposia taking place Monday, Oct. 28.
“We are committed to building clinical data and evidence for robotic angioplasty,” said David Handler, President and CEO of Corindus Vascular Robotics. “Through this symposium, we will illustrate the significant impact robotic angioplasties could have on increasing procedural precision and potentially improving clinical outcomes.”
“Optimizing PCI with Robotic Angioplasty” will feature the following speakers:
- Optimized PCI: From Gruentzig to CorPath - David R. Holmes, M.D., Mayo Clinic
- Introduction to Robotic Angioplasty - Ronald P. Caputo, M.D., St. Joseph's Hospital
- From PRECISE to PRECISION: Evidence-Based Robotics - Giora Weisz, M.D., New York-Presbyterian Hospital/Columbia University Medical Center
- One Stent Per Lesion Using Precise Measurement: Case 1 - Tom Stys, M.D., Sanford Health
- Complex Coronary Robotic-Enhanced Angioplasty: Case 2 - Theodore L. Schreiber, M.D., Detroit Medical Center
For a demonstration of robotic angioplasty with the CorPath System, register here and visit TCT booth #1117.
About Corindus Vascular Robotics
Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company’s FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a “One Stent Promise,” offering a $1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit www.corindus.com.